SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms Inc. is experiencing a sharp sell-off as investors react to unfavorable court rulings regarding addictive content and rising concerns over heavy AI capital expenditure. The community is actively debating whether this decline represents a major buying opportunity due to strong fundamentals or a deeper structural shift in social media regulation.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as investors react to volatility driven by reports of Google's new memory compression technology, which some fear could reduce future demand for traditional memory chips. The community remains deeply divided, with many bulls highlighting the company's strong fundamentals and critical role in the AI supply chain, while others are caught in a broader market sell-off triggered by geopolitical tensions and concerns over cyclicality.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is experiencing extreme volatility as traders grapple with escalating geopolitical tensions and erratic energy markets, fueling intense community debate over whether to buy the dip or prepare for further downside. Investors are closely monitoring potential diplomatic developments regarding the Strait of Hormuz, with the discourse split between those aggressively scalping the swings and others cautioning that leveraged semi-conductor exposure remains a risky play amidst broader economic uncertainty.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is seeing renewed positive momentum driven by a strategic ad partnership with Pacvue that expands its enterprise-scale advertising capabilities. Investors are closely watching ongoing insider buying, which appears to be tempering concerns surrounding previous executive stock sales.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is gaining momentum as investors eye its dual GLP-1/GIP agonist, VK2735, as a high-potential challenger in the multibillion-dollar obesity market. The community remains focused on upcoming trial milestones, viewing the stock as a prime acquisition target due to its clinical progress and clean profile relative to competitors.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals is seeing heightened investor attention and a strong upward trend, driven by robust commercial execution of its lead therapy, Rezdiffra, and speculation regarding potential long-term acquisition interest from major biopharma players. While the community is actively debating the company's high operating expenses versus its market leadership in the MASH space, technical momentum and positive analyst coverage continue to fuel significant bullish sentiment.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Kodiak Sciences is surging after the GLOW2 Phase 3 study for its eye drug, Zenkuda, met primary endpoints with superior results compared to sham treatment. The community is actively discussing a potential short squeeze due to high short interest, while debating whether the current move marks a long-term rerating of the company's platform or a temporary spike prone to profit-taking.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd

Wave Life Sciences is experiencing heightened market attention following a volatile reaction to interim clinical data for its obesity candidate, WVE-007, which has sparked intense debate over its long-term potential compared to GLP-1 incumbents. While some investors are bullish on the company's RNA-based platform and its unique ability to reduce visceral fat while preserving muscle mass, others remain skeptical about the trial design and are wary of potential further downside as analysts balance ambitious price targets against the challenges of a crowded obesity pipeline.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV investors are reacting negatively to a recent reverse stock split, with many in the community expressing extreme frustration over a lack of communication from management and a sharp decline in share price. Discussion is dominated by concerns over the company's long-term viability, allegations of market manipulation, and intense debate regarding whether the stock is an oversold buying opportunity or a value trap heading toward bankruptcy.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing significant selling pressure as investors grapple with concerns over high AI capital expenditures and a potential slowdown in software revenue growth, leading to a persistent decline in share price. The community is deeply divided between those viewing the current drop as an oversold, generational buying opportunity and those fearing a deeper structural breakdown in the stock's long-term momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CytomX Therapeutics (NASDAQ:CTMX) Given New $12.00 Price Target at Piper Sandler

Piper Sandler upped their target price on shares of CytomX Therapeutics from $10.00 to $12.00 and gave the stock an "overweight" rating in a report on Monday...

CytomX Therapeutics (NASDAQ:CTMX) CEO Sells $763,780.98 in Stock

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) CEO Sean Mccarthy sold 118,969 shares of the firm's stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total transaction of $763,780.98. Following the sale, the chief executive...

Yu-Waye Chu Sells 21,279 Shares of CytomX Therapeutics (NASDAQ:CTMX) Stock

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) insider Yu-Waye Chu sold 21,279 shares of CytomX Therapeutics stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $6.42, for a total value of $136,611.18. Following the completion of the transaction...

Sean Mccarthy Sells 118,969 Shares of CytomX Therapeutics (NASDAQ:CTMX) Stock

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) CEO Sean Mccarthy sold 118,969 shares of the stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total value of $763,780.98. Following the transaction, the chief executive officer directly...

Insider Selling: CytomX Therapeutics (NASDAQ:CTMX) SVP Sells 31,492 Shares of Stock

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) SVP Marcia Belvin sold 31,492 shares of the business's stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $6.42, for a total transaction of $202,178.64. Following the transaction, the senior vice...

CytomX Therapeutics (NASDAQ:CTMX) CFO Sells $124,053.66 in Stock

CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) CFO Christopher Ogden sold 19,323 shares of the stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total value of $124,053.66. Following the completion of the sale, the chief financial...

CytomX Therapeutics (NASDAQ:CTMX) Given New $16.00 Price Target at Barclays

Barclays boosted their price objective on shares of CytomX Therapeutics from $10.00 to $16.00 and gave the company an "overweight" rating in a report on Thursday...

CytomX Therapeutics (NASDAQ:CTMX) Shares Gap Up After Analyst Upgrade

CytomX Therapeutics (NASDAQ:CTMX) Shares Gap Up Following Analyst Upgrade...

Penny Stocks To Keep An Eye On - March 18th

CytomX Therapeutics, Datavault AI, and Eightco are the three Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are shares of very low-priced companies commonly...

<ul class="summary-bullets"><li>Guggenheim also raised its price target on CytomX Therapeutics to $15 from $10 and kept a ‘Buy’ rating on the shares.</li><li>Jefferies sees as much as a $5 billion market opportunity for Varseta-M.&nbsp;</li><li>According to data from Koyfin, all the nine analysts covering CTMX rate it ‘Buy’ or higher.</li></ul><p>Multiple analysts raised their price target on shares of CytomX Therapeutics Inc (CTMX) on Wednesday on the heels of the company announcing positive early-stage trial data from lead asset Varseta-M.</p><p>One of the analysts raised the price target on the stock to $18, representing a potential upside of about 230% from the stock’s last closing price on Tuesday.</p><h2 class="st-heading-2">Trial Data Stokes Optimism</h2><p>Earlier this week, the company announced positive data for Varseta-M in late-line metastatic colorectal cancer. The company said about 32% of patients responded to the treatment at the higher dose and 20% at the lower dose, with the disease kept from worsening for a median of around 7 months in both groups. The drug helped control the cancer in more than 80% of patients, and most side effects were considered manageable, the company said.</p><p>CytomX said it plans to engage with the U.S. Food and Drug Administration (FDA) mid-year to align on a potential registrational study. The company is also testing Varseta-M in combination with Bevacizumab, a therapy that blocks the blood supply to tumors.</p><p>Multiple analysts hiked their price targets on the stock following the update, with Jefferies and Guggenheim being the latest to join the parade.</p><h2 class="st-heading-2">Fresh Analyst Take</h2><p>Jefferies raised the firm's price target on CytomX Therapeutics to $16 from $8 and kept a ‘Buy’ rating on the shares following the "impressive" Phase 1 Varseta-M data update in late-line metastatic colorectal cancer (mCRC). The firm sees a buying opportunity with "a rare ADC asset" capable of generating about a $1 billion-plus opportunity in third-line and later mCRC alone, with potential to about $5 billion-plus as it moves into first and second-line, the analyst told investors.</p><p>Guggenheim also raised its price target on CytomX Therapeutics to $15 from $10 and kept a ‘Buy’ rating on the shares. The firm, which is updating its model and estimates following the company's recent disclosure, said the data for both the 8.6 and 10mg/kg dose levels exceeds the benchmarks for current standard of care options by "a wide margin," which justifies increasing its view of the odds of success to 60% from 30%, previously.</p><p>According to data from Koyfin, all the nine analysts covering CTMX rate it ‘Buy’ or higher. The average 12-month price target on the stock is $11.67, representing a potential upside of over 150% from current trading levels.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment for CTMX stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.</p><p><a href="https://stocktwits.com/symbol/CTMX">CTMX</a> has risen 671% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/eric-trump-says-abtc-has-more-bitcoin-than-glxy/cZ371mWRIgD">Eric Trump Says ABTC Has More Bitcoin Than GLXY – Stock Still Falls Amid Bitcoin’s Decline</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the CytomX Therapeutics logo is displayed on the screen of a tablet.

CTMX Stock Garners Price Target Revisions After Colorectal Cancer Trial Data: Jefferies Sees As Much As 230% Upside

Jefferies raised its price target to $18, representing a potential upside of about 230% from the stock’s last closing price on Tuesday.

Equity

Jefferies raised its price target to $18, representing a potential upside of about 230% from the stock’s last closing price on Tuesday.


CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

CytomX Therapeutics Inc

Alphabet $GOOGL

Robinhood $HOOD

Rocket Lab $RKLB

Sandisk $SNDK

The ticker that owned the conversation. This award honors the stock that defined the market narrative through engagement, price action, and cultural presence on the boards.

CTMX
CytomX Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CTMX News

CTMXCytomX Therapeutics Inc